High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial)

High-dose prednisolone may not be superior to a low-dose 6-week regimen in improving clinical, physiological and radiological outcomes, or health-related quality of life, in patients with symptomatic post-COVID-19 diffuse parenchymal lung abnormalities https://bit.ly/32zqnXt

Detalles Bibliográficos
Autores principales: Dhooria, Sahajal, Chaudhary, Shivani, Sehgal, Inderpaul Singh, Agarwal, Ritesh, Arora, Siddhant, Garg, Mandeep, Prabhakar, Nidhi, Puri, Goverdhan Dutt, Bhalla, Ashish, Suri, Vikas, Yaddanapudi, Lakshmi Narayana, Muthu, Valliappan, Prasad, Kuruswamy Thurai, Aggarwal, Ashutosh Nath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850687/
https://www.ncbi.nlm.nih.gov/pubmed/34887325
http://dx.doi.org/10.1183/13993003.02930-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850687/
https://www.ncbi.nlm.nih.gov/pubmed/34887325
http://dx.doi.org/10.1183/13993003.02930-2021

Ejemplares similares